4//SEC Filing
GRAINGER DAVID J 4
Accession 0001847903-23-000029
CIK 0001847903other
Filed
Jan 12, 7:00 PM ET
Accepted
Jan 13, 5:46 PM ET
Size
6.8 KB
Accession
0001847903-23-000029
Insider Transaction Report
Form 4
GRAINGER DAVID J
Chief Innovation Officer
Transactions
- Tax Payment
Ordinary Shares
2022-09-30$4.25/sh−7,154$30,405→ 906,602 total
Holdings
- 27,500(indirect: See footnote)
Ordinary Shares
Footnotes (5)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units.
- [F3]Shares held by the Reporting Person after the reported transaction herein and does not include shares acquired or disposed of in subsequent reported transactions after September 30, 2022.
- [F4]As of year end December 31, 2022, the Reporting Person held 904,105 shares directly.
- [F5]Held by RxCelerate Limited ("RxCelerate"). The Reporting Person is a member of the board of directors of RxCelerate. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by RxCelerate, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.
Documents
Issuer
Centessa Pharmaceuticals plc
CIK 0001847903
Entity typeother
Related Parties
1- filerCIK 0001887115
Filing Metadata
- Form type
- 4
- Filed
- Jan 12, 7:00 PM ET
- Accepted
- Jan 13, 5:46 PM ET
- Size
- 6.8 KB